Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Cereno Scientific strengthens its Executive Management Team with Head of Clinical Operations

Cereno Scientific (XSAT: CRNO B) today announced the recruitment of Fredrik Frick as Head of Clinical Operations. The appointment adds another experienced research and development (R&D) executive to Cereno’s management team, thereby further strengthens the R&D organization as the Company’s pipeline builds and progresses through preclinical and clinical studies.“The development of our pipeline is a critical success factor for Cereno in order to deliver on our vision to make available innovative drugs for patients with rare and common cardiovascular diseases. I am therefore delighted that we

Lipum’s GMP production of SOL-116 successful

Press release: Umeå, February 24, 2022. Lipum AB (publ) reports that the GMP manufacturing of SOL-116 has been successful and the drug product is now ready for aseptic fill and finish before use in clinical trials.Lipum's biological drug candidate SOL-116 has successfully been manufactured under the regulations that apply to Good Manufacturing Practice (GMP). The manufacturing work was done by the company’s partner Abzena Inc. in San Diego. For the next development step, Apotek Produktion & Laboratorier AB (APL) has been engaged for aseptic fill and finish which is the final, critical step

Year-end report 2021, January 1 – December 31

October - December 2021 Net revenue for the period was SEK 155.0 million (96.8), an increase of 60.1 %. Organic growth was 12.8 %. Adjusted EBITDA for the period was SEK 19.0 million (12.6) EBITDA for the period was SEK 19.4 million (16.3) Adjusted profit/loss for the period was SEK 3.8 million (2.4) Basic earnings per share for the period amounted to SEK 0.01 (0.05) Orders received for the period totaled SEK 177.6 million (99.0) Operating cash flow for the period was SEK 27.1 million (25.6) January - December 2021 Net revenue for the period was SEK 466.0 million (

Notification in accordance with the Finnish Securities Market Act Chapter 9 § 5: BlackRock, Inc.’s holding in Wärtsilä Corporation

Wärtsilä Corporation, Flagging notification, 24 February 2022 at 9:45 am EETNotification in accordance with the Finnish Securities Market Act Chapter 9 § 5: BlackRock, Inc.’s holding in Wärtsilä CorporationBlackRock, Inc. has informed Wärtsilä Corporation that it has crossed above the 5% disclosure limit on total holding in shares and voting rights on 22 February 2022. Following the transaction, BlackRock, Inc. owns 4.81% of Wärtsilä’s shares and voting rights, while its total holding in Wärtsilä Corporation corresponds to 5.01%. Total position of BlackRock, Inc. and its funds subject

The subscription price for the exercise of warrants of series TO1 in Veg of Lund has been determined to SEK 11,06 per share

During the third quarter of 2021 Veg of Lund AB (publ) (“Veg of Lund” or the “Company”) carried out an issue with deviation from the shareholders’ pre-emption rights (the “Directed issue”) of so called units consisting of shares and warrants of series TO1 (“Warrants”) and an issue of Warrants to the, at that time, existing shareholders in Veg of Lund for the purpose of compensating the existing shareholders for the dilution effect which followed from the Directed issue (the “Compensation issue”). The subscription price for the shares which are subscribed for through the exercise of the

AcouSort: Interim Report 2021-10-01 – 2021-12-31

Fourth quarter (2021-10-01 – 2021-12-31) • Income amounted to TSEK 535 (1 181) • Result before tax amounted to TSEK -3 585 (-3 404) • Result per share* was SEK -0.27 (-0.30)   Twelve months (2021-01-01 – 2021-12-31) • Income amounted to TSEK 3 007 (4 928) • Result before tax amounted to TSEK -12 200 (-7 978) • Result per share was SEK -0.92 (-0.70) • Equity ratio amounted to 90 % (73 %) on 31 December 2021   CEO Comments During the last quarter of the year, we noted that the business climate slowly but surely began to return to more normal patterns. We

Swedbank Robur Sustainable Investments 2021

Swedbank Robur's annual report Sustainable Investments presents how the fund company integrate and work to support and drive sustainability issues in their investments. The report for 2021 shows, among other things, that Swedbank Robur expanded the number of funds secured to be managed in line with the Paris Agreement, launched a new fund focusing on the climate issue and how the work with the implementation of the new EU SFDR* regulations is proceeding."We have had since long a strong focus on sustainability, and in particular the climate issue. Our sustainability work is today well

Year End Report Scandinavian Enviro Systems AB (publ) January – December 2021

Q4 2021 · Net revenues for the period were MSEK 1.0 (0.4) · Earnings after tax for the period were MSEK -18.6 (-13.7) · Earnings per share for the period (before dilution) was SEK -0.03 (-0.02) · Cash flow for the period after investments was MSEK -16.6 (-14.4) · Enviro completes a directed new share issue, raising approximately SEK 125 million before transaction costs where Michelin has invested to retain its ownership of 20%. · Enviro decides on location and applies for environmental permit for recycling plant in Uddevalla Jan-Dec 2021 · Net revenues for the

Bluestep Bank AB (publ) Year-end report 2021

The year in brief   Performance and financial position · Lending to the public increased by 14% to SEK 18 333m (SEK 16 116m). Adjusted for currency effects the increase was 10%. All countries are showing a positive portfolio development, mainly driven by increased lending to customer segments with lower risk. · New lending for the year increased by 16% to SEK 7 169m (SEK 6 197m). Adjusted for the personal loan portfolio and currency effects the increase was also 16%, as the difference in new lending of personal loans in 2020 was equivalent to the currency effects in 2021. ·

Cantargia publishes full year report for 2021

Cantargia AB’s (”Cantargia”) full year report for 2021 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the fourth quarter · Updated encouraging survival data were reported from the CANFOUR trial with nadunolimab and chemotherapy in pancreatic cancer (PDAC) · Nadunolimab was granted orphan drug status for treatment of PDAC by the European Medicines Agency (EMA) · The first patient was treated in the CESTAFOUR trial · Two scientific articles on nadunolimab were published in peer-reviewed journals · Positive

Christer Norström appointed acting chairman of Realheart

Christer Norström, born 1961, is appointed acting chairman of the board of Realheart, of which he has been a member since 2021. He replaces former chairman Göran Hellers who recently passed away, as previously announced.Christer Norström has extensive experience from both academia and industry. He holds a PhD in engineering and is an associate professor in mechatronics and professor in computer engineering. Christer Norström is currently CEO of ABB Industrial High School and a member of the Royal Swedish Academy of Engineering Sciences, IVA. He also holds board positions in Prindit

ExpreS2ion announces financial results for the fourth quarter and full-year 2021

Hørsholm, Denmark, February 24, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its fourth quarter and full year financial results for 2021. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments “In 2021, ExpreS[2]ion was able to deliver strong progress in key areas related to our ongoing transition into a stronger and much more pipeline-driven biotechnology company with high-value assets based on our novel ExpreS2 technology platform for the development and

Annual Report for the fiscal year 2021

Curasight A/S (“Curasight” or “the Company”) hereby publishes the Annual Report for the fiscal year of 2021. The Annual Report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Curasight’s CEO Ulrich Krasilnikoff comments: “During the past year, we have seen promising results from multiple academic investigator-initiated phase II studies regarding indications in prostate, head and neck cancer as well as in neuroendocrine tumors. It is motivating to see how the interest in Curasight and our technology is continuously growing

Interim report Q4, 2021

Fourth quarter · Net sales amounted to SEK 23.1 (8.4) million · EBITDA amounted to SEK 0.3 (-7.2) million · EBIT amounted to SEK -75.1* (-15.2) million · EBT amounted to SEK -76,5 (-21.2) million · The Board of SpectrumOne has applied for the Swedish Companies Registration Office's approval to distribute 374,220,904 shares in Observit AB to existing shareholders Full year · Net sales amounted to SEK 60.8 (14.8)  million · EBITDA amounted to SEK -6.3 (-14.9) million · EBIT amounted to SEK -147,2* (-38.6) million  · EBT amounted to SEK -157.0 (-25.6)

Fuud launches LEGENDZ – clean carbonated drinks inspired by the gaming universe

STOCKHOLM, 24 Feb, 2022 08.30 CET Fuud announces the launch of an exciting new brand of gaming drinks for gamers wanting clean refreshment. Upon release, 3 uniquely crafted LEGENDZ characters offering 3 different appetizing flavors will land on shelves across Sweden. The drinks can be found at selected stores from week 6.Louise Nobel, CMO at Fuud: “With LEGENDZ, we want to provide gamers with a healthy and tasty alternative to energy drinks. We love the world of gaming and want to pay homage to its lore, traditions, and to the many games that inspire us. We also want to show respect to

Nordic Capital-backed Vizrt Group appoints Klaus Holse as chairperson to accelerate growth

Vizrt Group, a global leader in software for live video production, has appointed Klaus Holse as new Chairperson. With a background as CEO of SimCorp, Corporate VP at Microsoft, and Senior VP at Oracle, Klaus will support Vizrt Group’s further growth and expansion.“I am delighted to be appointed Chairperson of Vizrt Group and I am excited to support its continued transition to a SaaS business model. The group has great potential for further growth with its leading technology platform, strong customer relationships and reputation for operational excellence. I’m looking forward to working

Transcom Holding AB (publ): Year-end-report 2021

Fourth quarter 2021 highlights · Revenue increased to 175.3M€ (157.4) · EBITDA excluding non-recurring items* increased to 26.2M€ (23.7) · EBITDA margin excluding non-recurring items amounted to 14.9% (15.1%) · Operating cash flow amounted to 4.3M€ (8.5) · Net debt/EBITDA* amounted to 4.1 (3.3) January-December 2021 · Revenue increased to 623.1M€ (557.8) · EBITDA excluding non-recurring items* increased to 74.8M€ (70.8) · EBITDA margin excluding non-recurring items amounted to 12.0% (12.7%) · Operating cash flow amounted to 22.0M€ (50.3) Comments by the

Interim Report Fourth Quarter and Annual Financial Statement Release 2021

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2021 – 31.12.2021. The report, which has not been reviewed by the Company’s auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: ”In Q4 and 2021 in general our endurance was tested once again in terms of commercial traction. On the other hand, we experienced solid progress on all other fronts: · International sales are

LeadDesk continues growing with two acquisitions and new enterprise customers

LeadDesk Plc press release 24 February 2022, 9:10Unofficial translation of company release 24 February 2022, 9:00 am. In case the document differs from the original, the Finnish version prevails. LeadDesk Plc FINANCIAL STATEMENTS 1/1–31/12/2021 Figures in parenthesis refer to the equivalent period in the previous year, unless otherwise stated. Figures presented in this press release are unaudited.  July-December 2021 · Revenue EUR 12,545 (7,588) thousand, growth 65.3% · Comparable pro forma revenue* EUR 14,110 (12,339*) thousand, growth 14.4% · Annual recurring revenue

Year-end Report January – December 2021

lmportant commercial progress · New CEO appointed. · First commercial hydrogen project. · Air Quality sensor integrated in AAC's customer offer. Outcome October-December · Net sales amounted to 680 (23) kSEK. · Profit after net financial items amounted to -3,041 (-4,494) kSEK. · Basic and diluted earnings per share: -0,23 (-0,41) SEK. · Cash flow from operating activities and investing activities: -1,360 (-2,207) kSEK. Outcome January-December · Net sales amounted to 2,335 (1,177) kSEK. · Profit after net financial items amounted to -11,620 (-12,795)

Alzinova AB Year end report 2021

The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the year end report for the period January - December 2021Twelve months, January – December 2021 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -7,552,006 SEK (-6,499,557 SEK). · Earnings per share amounted to -0.48 SEK (-0.41 SEK). · Equity ratio amounted to 96.5% (95.2%). Three months, October – December 2021 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -2,455,624 SEK (-2,361,085 SEK). · Earnings per share

Asarina Pharma AB (publ) Year-end Report 2021 released

Peter Nordkild, CEO: “We enter the new financial year with renewed energy and optimism after Region Hovedstaden finally signed the required papers for our clinical test sites in Copenhagen, and we achieved ‘First Patient First Visit’ on 16 February in our phase IIa clinical study in Tourette syndrome. We are now moving ahead confidently in our search to develop a safer, entirely novel modality of treatment for Tourette syndrome, and, potentially, OCD.”FINANCIAL HIGHLIGHTS · Total operating expenses in Q4/21 reduced to 8.7 MSEK (24.9 MSEK in Q4/20) · Cash balance at 31 December 2021

Fourth quarter report Q4-2021 - preparing for the pivotal trial

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 October – 31 December 2021. The fourth quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports. The company is progressing with planned activities: Recruitment of trial 0206 is progressing (a trial to investigate the pharmacokinetics in children aged 1-17 undergoing elective surgical procedures) and we are currently finalising the preparation for the initiation of our pivotal trial with CT001 (0205). We anticipate the results from

Bricknode year-end report 2021

Highlights 2021 · Successful IPO completed with first day of trading on 9 November 2021 · Net revenue increased by 33% to 15,385 (11,578) TSEK · Net revenue retention rate: 115% · Agreement signed with a large international investment bank · First family office customer onboarded · Two new FinTech companies onboarded to the platform · Key recruitments achieved to support development and growth Comments from the CEOs, Stefan Willebrand & Erik Hagelin: “Our customer base is growing, and it is a true pleasure to see international investment banks, robo-advisors,

There are no items matching the current filter
There are no more items matching the current filter
Back to top